HealthyPhase 1NCT05288673
A Study of Multiple Doses of ALXN1210 in Healthy Adult Participants
A Phase 1 study testing ALXN1210 in people with Healthy, run by Alexion Pharmaceuticals, Inc. at 1 site in United Kingdom.
Trial summary
This study evaluated the safety and tolerability of multiple doses of ALXN1210 (400 and 800 milligrams [mg]) following intravenous (IV) administration to healthy participants. Read more about this study
- Who is it for?
- Ages 25 to 55 yearsHealthy volunteers can take part
- Conditions the study is for
- Healthy
- What is being tested?
- ALXN1210
- Type of treatment
- Injection or infusion
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 16 participants
- Where
- 1 siteUnited Kingdom
- Study dates
- 28 Jul 2015to 1 Sep 2016
- Phase
- Phase 1
- Are there results?
- Yes, posted in the registrySummary in the doctors' view
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 25 to 55 years
- All sexes
- Healthy volunteers accepted
- Adult
Who may be able to join
- Healthy male and female participants ≥ 25 and ≤ 55 years old; smokers (no more than 10 cigarettes daily), former smokers (at the Investigator's discretion), or nonsmokers.
- Body mass index from 18 through 29.9 kilogram (kg)/square meter, inclusive, and weight between 50 and 100 kg, inclusive.
- QT interval (corrected using the Fridericia formula) ≤ 450 milliseconds (ms) for males and ≤ 470 ms for females at Screening and prior to dosing on Day 1.
- Participant was willing and able to give written informed consent and comply with the study visit schedule.
- Documented vaccination with tetravalent meningococcal conjugate vaccine (MCV4) at least 56 days and not more than 3 years prior to dosing. Documentation must have included a positive serum bactericidal antibody test to confirm an immune response before the study drug administration.
- Vaccination with serogroup B vaccine at least 56 days prior to dosing on Day 1, with a booster administered at least 28 days prior to dosing on Day 1.
- Male participants with a female spouse/partner of childbearing potential or a pregnant or breastfeeding spouse or partner were required to use barrier contraception (male condom) during the treatment period and for at least 6 months after the last dose of ALXN1210.
Who cannot join
- Participants who had intimate and prolonged contact (defined as living under the same roof or providing personal care) with individuals who were either immunocompromised, or had specific underlying medical conditions (persons with anatomic or functional asplenia [including sickle cell disease]; persons with congenital complement, properdin, factor D, or primary antibody deficiencies, persons with acquired complement deficiencies [for example, those receiving eculizumab], and persons with human immunodeficiency virus [HIV]) or with persons younger than 2 years of age or older than 65 years of age
- Participants who were one of the following: professionals exposed to environments of greater risk for meningococcal disease; research, industrial, and clinical laboratory personnel routinely exposed to Neisseria meningitidis; military personnel during recruit training (military personnel may be at increased risk when accommodated in close quarters); daycare center workers; those living on a college or university campus; or those who planned to travel during the course of the study to or had travelled to endemic areas for meningococcal meningitis (for example, India, Sub-Saharan Africa, pilgrimage to Saudi Arabia for Hajj) within the past 6 months
- History of any Neisseria infection
- History of unexplained recurrent infection or infection that required treatment with systemic antibiotics within the last 90 days prior to dosing
- HIV infection (evidenced by HIV-1 or HIV-2 antibody titer)
- Acute or chronic hepatitis B virus infection (evidenced by the presence of hepatitis B surface antigen or immunoglobulin M antibodies against hepatitis B core antigen)
Show all 31Show fewer
- Acute or chronic hepatitis C virus infection (evidenced by antibody titer)
- Active systemic viral or fungal infection within 14 days prior to dosing
- Positive or indeterminate QuantiFERON-TB test indicating possible tuberculosis infection
- History of latent or active tuberculosis or exposure to endemic areas within 8 weeks prior to the screening visit
- Female participants who were breastfeeding or were of childbearing potential, including any female who had experienced menarche and who had not undergone successful surgical sterilization (hysterectomy, bilateral tubal ligation, or bilateral oophorectomy) or who was pregnant, breastfeeding, or not postmenopausal.
- Positive serum pregnancy test at Screening or Day -1
- Serum creatinine > upper limit of normal (ULN) of the reference range of the testing laboratory at Screening or Day -1.
- Alanine aminotransferase or aspartate aminotransferase > ULN of the reference range of the testing laboratory at Screening or > 1.5*ULN of the reference range of the testing laboratory at Day -1.
- Any of the following hematology results: hemoglobin < 135 grams (g)/L for males and < 120 g/L for females; hematocrit < 0.41 L/L for males and < 0.36 L/L for females; white blood cells < 3.5*10^3/microliter (μL) or > ULN of the testing laboratory reference range; absolute neutrophils < 1.5*10^3/μL (< 1.0*10^3/μL for black race participants) or > ULN of the testing laboratory reference range; and platelets < the lower limit of normal of the testing laboratory reference range or > 450*10^3/μL at Screening or Day -1; or complete blood count clinical laboratory results considered as clinically relevant and unacceptable by the Investigator at Day -1.
- History of complement deficiency or complement activity below normal reference range as evaluated by complement alternative pathway enzyme-linked immunosorbent assay at Screening.
- History of malignancy, other than basal cell carcinoma that had been treated and had no evidence of recurrence.
- Participation in a clinical study within 30 days before initiation of dosing on Day 1 or use of any experimental small-molecule therapy within 30 days prior to dosing on Day 1.
- Participation in more than 1 clinical study of a monoclonal antibody (mAb) or participation in a clinical study of a mAb within the 12 months prior to Screening during which the participant was exposed to the active study drug. Participants who had participated in only 1 study of an mAb were considered for enrollment if they had completed that study more than 12 months prior to Screening.
- Major surgery or hospitalization within 90 days prior to dosing.
- Contraindication to receiving MCV4 and/or serogroup B vaccine, including severe (life-threatening) allergic reaction to a previous dose of MCV4 and/or serogroup B vaccine, severe (life-threatening) allergy to any vaccine component, or previous diagnosis of Guillain-Barré syndrome.
- History of allergy to excipients of ALXN1210 (that is, polysorbate 80).
- Documented history of allergy to penicillin or cephalosporin.
- History of significant allergic reaction (anaphylaxis, angioedema) to any product (food, pharmaceutical, etc).
- Positive urine drug toxicology screen at Screening or Day -1.
- Donation of plasma within 7 days prior to dosing. Donation or loss (excluding volume drawn at Screening) of more than 50 mL of blood within 30 days of dosing or more than 499 mL of blood within 56 days of dosing.
- Use of prescription medications within 28 days prior to study drug administration.
- Clinical diagnosis of any autoimmune or rheumatologic disease (for example, systemic lupus erythematosus, rheumatoid arthritis).
- Immunization with a live-attenuated vaccine 1 month prior to dosing or planned vaccination during the course of the study (except for the vaccination planned by the study protocol).
- Presence of fever (confirmed body temperature > 37.6°C; for example, a fever associated with a symptomatic viral or bacterial infection) within 14 days prior to the first dose.
- Participants with any medical history, conditions or risks that, in the opinion of the Investigator, would have interfered with the participant's full participation in the study or compliance with the protocol, posed any additional risk for the participant, or confounded the assessment of the participant or outcome of the study.
Trial locations and contacts
1 site in 1 country.
About this study
Official title: A Phase 1, Randomized, Blinded, Placebo-Controlled, Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Immunogenicity, Pharmacokinetics, and Pharmacodynamics of ALXN1210 Administered Intravenously to Healthy Subjects
This study evaluated the safety and tolerability of multiple doses of ALXN1210 (400 and 800 milligrams [mg]) following intravenous (IV) administration to healthy participants.
Read the detailed description
Participants were divided into 2 cohorts and were randomly assigned in a 3:1 ratio to receive IV ALXN1210 or placebo. Participants in Cohort 1 received 5 IV doses of 400 mg of ALXN1210 or placebo administered every 28 days. To determine if dose continuation and dose escalation to Cohort 2 should occur, the Safety Review Committee conducted a blinded review of the available safety data after Day 15 of the second dose of the last participant in Cohort 1. Participants in Cohort 2 received 5 doses of 400 mg of ALXN1210 or placebo and 5 IV doses of 800 mg of ALXN1210 or placebo administered intravenously every 28 days. Safety, PK, PD, and immunogenicity assessments were performed during the Follow-up Period after the last dose.
- Conditions
- Healthy
- Being tested
- ALXN1210, Placebo
- Keywords
- ALXN1210, Pharmacokinetics, Pharmacodynamics
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
ALXN1210Drug
Also called Ultomiris, Ravulizumab
ALXN1210 was administered by IV infusion over 5 periods, 1 dose per period: Period 1, induction; Periods 2-5, maintenance. Participants received a total of 5 doses of 400 or 800 mg, each administered every 28 days.
PlaceboDrug
Placebo was administered by IV infusion over 5 periods, 1 dose per period. Participants received the same volume and infusion rate as specified for each ALXN1210 dose (400 or 800 mg).
| Study group | Role | What they receive |
|---|---|---|
| ALXN1210 400 mg | Experimental | Participants received ALXN1210 every 28 days. Receives: Drug: ALXN1210 |
| ALXN1210: 800 mg | Experimental | Participants received ALXN1210 every 28 days. Receives: Drug: ALXN1210 |
| Placebo | Placebo comparator | Participants received placebo every 28 days. Receives: Drug: Placebo |
What is being measured
The primary outcome is the main question the study is designed to answer.
Number of Participants With Treatment-Emergent Adverse Events (TEAEs)
An adverse event (AE) was defined as any unfavorable and unintended sign (for example, including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal product or procedure, whether or not considered related to the medicinal product or procedure, which occurred during the course of the clinical study. TEAEs were defined as AEs that occurred on or after the date and time of study drug administration, or those that first occurred before dosing but worsened in frequency or severity after study drug administration. A summary of all Serious Adverse Events and Other Adverse Events (nonserious) regardless of causality is located in the 'Reported Adverse Events' Section.
Measured: Baseline up to Day 309
Secondary outcomes (8)
Area Under The Serum Concentration Versus Time Curve From Time Zero To Infinity (AUCinf) of ALXN1210
Blood samples were collected for estimation of AUCinf by noncompartmental analyses using Phoenix WinNonlin 6.3 or higher.
Measured: Predose, end of infusion, 30 minutes, 4 hours, 8 hours and 24 hours post start of infusion on Day 1 up to Day 309
Area Under The Serum Concentration From Time Zero To The Time of The Last Quantifiable Concentration (AUCt) of ALXN1210
Blood samples were collected for estimation of AUCt by noncompartmental analyses using Phoenix WinNonlin 6.3 or higher.
Measured: Predose, end of infusion, 30 minutes, 4 hours, 8 hours and 24 hours post start of infusion on Day 1 up to Day 309
Maximum Observed Serum Concentration (Cmax) of ALXN1210
Blood samples were collected for estimation of Cmax by noncompartmental analyses using Phoenix WinNonlin 6.3 or higher.
Measured: Predose, end of infusion, 30 minutes, 4 hours, 8 hours and 24 hours post start of infusion on Day 1 up to Day 309
Percent Change From Baseline in Free Complement Protein C5 Concentration at Day 113
Blood samples were collected for analysis of free C5 concentration.
Measured: Baseline, Day 113
Percent Change From Baseline in Total C5 Concentration at Day 113
Blood samples were collected for analysis of total C5 concentration.
Measured: Baseline, Day 113
Percent Change From Baseline in Chicken Red Blood Cell Hemolysis at Day 113
Blood samples were collected for analysis of cRBC hemolysis.
Measured: Baseline, Day 113
Percent Change From Baseline in C5 Activation at Day 113
Blood samples were collected for analysis of C5 activation. Results are reported as percent change in both the complement classical pathway (CCP) activity response and the complement alternative pathway (CAP) activity response.
Measured: Baseline, Day 113
Number of Participants With Positive Antidrug Antibodies (ADAs) to ALXN1210
Blood samples were collected to evaluate antibody response through development of ADAs.
Measured: Baseline up to Day 309
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted21 Mar 2022
- Study start28 Jul 2015
- Primary completion1 Sep 2016
- Study completion1 Sep 2016
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Posted resultsParticipant flow, outcome measures and adverse events reported by the sponsor.
- Other trials for HealthyStudies of the same condition, open and under way.
- More trials run by Alexion Pharmaceuticals, Inc.The sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 1
- Primary purpose
- Basic science
- Allocation
- Randomised
- Intervention model
- Sequential
- Masking
- Triple blind
- Who is masked
- Participant, Care provider, Investigator
- Enrolment
- 16 participants (actual)
Sponsor and investigators
- Lead sponsor
- Alexion Pharmaceuticals, Inc.
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05288673
- Sponsor's protocol ID
- ALXN1210-HV-102
- Other IDs
- 2014-005495-29, 2014
- Status last verified
- Jun 2022
- First submitted
- 11 Mar 2022
- Last updated
- 9 May 2023
- Results posted
- Yes, on ClinicalTrials.gov
- Data monitoring committee
- No
- FDA-regulated drug
- Yes
- FDA-regulated device
- No
- Individual data sharing
- Yes: Alexion has a public commitment to allow requests for access to study data and will be supplying a protocol, CSR, and plain language summaries.
Study at a glance
From the registry record, last updated by the sponsor on 9 May 2023. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Phase 1, Randomized, Blinded, Placebo-Controlled, Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Immunogenicity, Pharmacokinetics, and Pharmacodynamics of ALXN1210 Administered Intravenously to Healthy Subjects
- ClinicalTrials.gov ID
- NCT05288673
- Acronym / sponsor ID
- ALXN1210-HV-102
- Conditions
- Healthy
- Keywords
- ALXN1210, Pharmacokinetics, Pharmacodynamics
- Phase
- Phase 1
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 16 participants (actual)
- Lead sponsor
- Alexion Pharmaceuticals, Inc.Industry (pharma, biotech, devices)
- Study start
- 28 Jul 2015 (actual)
- Primary completion
- 1 Sep 2016 (actual)
- Study completion
- 1 Sep 2016 (actual)
- First posted
- 21 Mar 2022 (actual)
- Results
- Posted 9 May 2023
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study evaluated the safety and tolerability of multiple doses of ALXN1210 (400 and 800 milligrams [mg]) following intravenous (IV) administration to healthy participants.
Detailed description
Participants were divided into 2 cohorts and were randomly assigned in a 3:1 ratio to receive IV ALXN1210 or placebo. Participants in Cohort 1 received 5 IV doses of 400 mg of ALXN1210 or placebo administered every 28 days. To determine if dose continuation and dose escalation to Cohort 2 should occur, the Safety Review Committee conducted a blinded review of the available safety data after Day 15 of the second dose of the last participant in Cohort 1. Participants in Cohort 2 received 5 doses of 400 mg of ALXN1210 or placebo and 5 IV doses of 800 mg of ALXN1210 or placebo administered intravenously every 28 days. Safety, PK, PD, and immunogenicity assessments were performed during the Follow-up Period after the last dose.
Study design
- Primary purpose
- Basic science
- Allocation
- Randomised
- Intervention model
- Sequential
- Masking
- Triple blind (participant, care provider, investigator)
- Number of arms
- 3
| Arm | Type | Receives |
|---|---|---|
| ALXN1210 400 mg | Experimental | Drug: ALXN1210Participants received ALXN1210 every 28 days. |
| ALXN1210: 800 mg | Experimental | Drug: ALXN1210Participants received ALXN1210 every 28 days. |
| Placebo | Placebo comparator | Drug: PlaceboParticipants received placebo every 28 days. |
Who may qualify
- Ages
- 25 to 55 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult
Key inclusion criteria (7 listed)
- Healthy male and female participants ≥ 25 and ≤ 55 years old; smokers (no more than 10 cigarettes daily), former smokers (at the Investigator's discretion), or nonsmokers.
- Body mass index from 18 through 29.9 kilogram (kg)/square meter, inclusive, and weight between 50 and 100 kg, inclusive.
- QT interval (corrected using the Fridericia formula) ≤ 450 milliseconds (ms) for males and ≤ 470 ms for females at Screening and prior to dosing on Day 1.
- Participant was willing and able to give written informed consent and comply with the study visit schedule.
- Documented vaccination with tetravalent meningococcal conjugate vaccine (MCV4) at least 56 days and not more than 3 years prior to dosing. Documentation must have included a positive serum bactericidal antibody test to confirm an immune response before the study drug administration.
Key exclusion criteria (31 listed)
- Participants who had intimate and prolonged contact (defined as living under the same roof or providing personal care) with individuals who were either immunocompromised, or had specific underlying medical conditions (persons with anatomic or functional asplenia [including sickle cell disease]; persons with congenital complement, properdin, factor D, or primary antibody deficiencies, persons with acquired complement deficiencies [for example, those receiving eculizumab], and persons with human immunodeficiency virus [HIV]) or with persons younger than 2 years of age or older than 65 years of age
- Participants who were one of the following: professionals exposed to environments of greater risk for meningococcal disease; research, industrial, and clinical laboratory personnel routinely exposed to Neisseria meningitidis; military personnel during recruit training (military personnel may be at increased risk when accommodated in close quarters); daycare center workers; those living on a college or university campus; or those who planned to travel during the course of the study to or had travelled to endemic areas for meningococcal meningitis (for example, India, Sub-Saharan Africa, pilgrimage to Saudi Arabia for Hajj) within the past 6 months
- History of any Neisseria infection
- History of unexplained recurrent infection or infection that required treatment with systemic antibiotics within the last 90 days prior to dosing
- HIV infection (evidenced by HIV-1 or HIV-2 antibody titer)
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| ALXN1210Also: Ultomiris, RavulizumabALXN1210 was administered by IV infusion over 5 periods, 1 dose per period: Period 1, induction; Periods 2-5, maintenance. Participants received a total of 5 doses of 400 or 800 mg, each administered every 28 days. | Drug | ALXN1210 400 mg, ALXN1210: 800 mg |
| PlaceboPlacebo was administered by IV infusion over 5 periods, 1 dose per period. Participants received the same volume and infusion rate as specified for each ALXN1210 dose (400 or 800 mg). | Drug | Placebo |
Primary outcome
Number of Participants With Treatment-Emergent Adverse Events (TEAEs)
Time frame: Baseline up to Day 309
An adverse event (AE) was defined as any unfavorable and unintended sign (for example, including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal product or procedure, whether or not considered related to the medicinal product or procedure, which occurred during the course of the clinical study. TEAEs were defined as AEs that occurred on or after the date and time of study drug administration, or those that first occurred before dosing but worsened in frequency or severity after study drug administration. A summary of all Serious Adverse Events and Other Adverse Events (nonserious) regardless of causality is located in the 'Reported Adverse Events' Section.
8 secondary outcomes
Area Under The Serum Concentration Versus Time Curve From Time Zero To Infinity (AUCinf) of ALXN1210
Time frame: Predose, end of infusion, 30 minutes, 4 hours, 8 hours and 24 hours post start of infusion on Day 1 up to Day 309
Area Under The Serum Concentration From Time Zero To The Time of The Last Quantifiable Concentration (AUCt) of ALXN1210
Time frame: Predose, end of infusion, 30 minutes, 4 hours, 8 hours and 24 hours post start of infusion on Day 1 up to Day 309
Maximum Observed Serum Concentration (Cmax) of ALXN1210
Time frame: Predose, end of infusion, 30 minutes, 4 hours, 8 hours and 24 hours post start of infusion on Day 1 up to Day 309
Percent Change From Baseline in Free Complement Protein C5 Concentration at Day 113
Time frame: Baseline, Day 113
Percent Change From Baseline in Total C5 Concentration at Day 113
Time frame: Baseline, Day 113
Percent Change From Baseline in Chicken Red Blood Cell Hemolysis at Day 113
Time frame: Baseline, Day 113
Percent Change From Baseline in C5 Activation at Day 113
Time frame: Baseline, Day 113
Number of Participants With Positive Antidrug Antibodies (ADAs) to ALXN1210
Time frame: Baseline up to Day 309
Results and safety
Loading the posted results from ClinicalTrials.gov…
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 9 May 2023.
- Posted resultsParticipant flow, baseline, all outcome measures and adverse events.
- Individual participant dataSharing planned: Yes. Alexion has a public commitment to allow requests for access to study data and will be supplying a protocol, CSR, and plain language summaries.
Related trials for Healthy
Recruiting
THE EFFECTS OF GAME-BASED EXERCISE PROGRAMS
Physical Activity, Body Image
Not yet recruitingPhase 1
A Phase I Study of GLR2053 Tablets in Chinese Healthy Adult Participants
Atopic Dermatitis
Recruiting
Colon-delivered Riboflavin and Gut Microbiota Composition
Microbiome Dysbiosis, Gut Health
Not yet recruiting
Neuroergonomic Analysis of a Brain-Computer Interface Device (BCI)
Healthy Volunteers - Male and Female
RecruitingPhase 1
First-in-Human Trial to Assess REGN20423 in Healthy Adult Participants and Adult Participants With Atopic Dermatitis
Healthy Volunteer, Atopic Dermatitis
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 1 study testing ALXN1210 in people with Healthy, run by Alexion Pharmaceuticals, Inc. at 1 site in United Kingdom.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 7 inclusion and 31 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 9 May 2023. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United Kingdom. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 1 studies test a treatment in a small group of people for the first time or in a new way, mainly to check safety and find the right dose.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
Yes. Results are posted in the registry (first posted 9 May 2023). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Number of Participants With Treatment-Emergent Adverse Events (TEAEs) (time frame: Baseline up to Day 309). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 9 May 2023.